These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18386289)

  • 1. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
    Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
    Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
    Tajiri M; Ohyama C; Wada Y
    Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
    Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
    Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
    Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
    Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
    Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
    Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
    Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
    Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel small molecule inhibitors for prostate-specific antigen.
    Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
    Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
    Robert M; Gibbs BF; Jacobson E; Gagnon C
    Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma.
    Bindukumar B; Kawinski E; Cherrin C; Gambino LM; Nair MP; Schwartz SA; Chadha KC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):113-20. PubMed ID: 15556523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different molecular forms of uncomplexed prostate specific antigen (PSA) show similar immunoreactivities.
    Chu LF; Chen Z; Stamey TA
    J Urol; 1999 Jun; 161(6):2009-12. PubMed ID: 10332491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic properties of prostate-specific antigen (PSA).
    Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
    Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic activity of PSA-derived peptides.
    Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
    Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
    Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
    Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.
    Peter J; Unverzagt C; Krogh TN; Vorm O; Hoesel W
    Cancer Res; 2001 Feb; 61(3):957-62. PubMed ID: 11221890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid.
    Okada T; Sato Y; Kobayashi N; Sumida K; Satomura S; Matsuura S; Takasaki M; Endo T
    Biochim Biophys Acta; 2001 Feb; 1525(1-2):149-60. PubMed ID: 11342264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid.
    Zhang WM; Leinonen J; Kalkkinen N; Dowell B; Stenman UH
    Clin Chem; 1995 Nov; 41(11):1567-73. PubMed ID: 7586544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.
    Bindukumar B; Schwartz S; Aalinkeel R; Mahajan S; Lieberman A; Chadha K
    Prostate; 2008 Oct; 68(14):1531-45. PubMed ID: 18646040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
    Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.